Drug Profile
Influenza virus vaccine trivalent - GC Biopharma
Alternative Names: GC 501; GC FLU; GCFlu®; Inactivated, split virion, influenza virus vaccine - GC Biopharma; Seasonal influenza virus vaccine - GC Biopharma; Trivalent influenza virus vaccine - GC BiopharmaLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 15 Mar 2011 Influenza virus vaccine trivalent (GC FLU®) receives WHO prequalification status for Influenza virus infections (prevention)
- 01 Jan 2010 Launched for Influenza virus infections in South Korea (IM)